Table 5 Predictors of cancer-specific mortality in patients with castration-resistant prostate cancer

Age

1.038

(1.016–1.061)

0.001

1.020

(0.998–1.042)

0.069

Body mass index

0.968

(0.901–1.041)

0.382

PSA^a

1.001

(1.000-1.001)

< 0.001

1.001

(1.000–1.001)

0.018

Hemoglobin^a

1.001

(0.999-1.002)

0.306

Albumin^a

0.408

(0.301-0.553)

< 0.001

Alkaline phosphatase^a

1.001

(1.000–1.001)

< 0.001

1.001

(1.001–1.002)

< 0.001

T stage (≥T3 vs. ≤T2)

0.865

(0.524–1.430)

0.271

N stage (1 vs. 0)

1.251

(0.922–1.697)

0.152

M stage (1 vs. 0)

1.528

(0.983–2.376)

0.062

Gleason score (≥8 vs. ≤7)

1.957

(1.441–2.658)

< 0.001

2.004

(1.452–2.767)

< 0.001

CCI ≥4

1.197

(0.811–1.765)

0.365

ECOG ≥2

1.802

(1.216–2.670)

0.003

1.304

(1.164–2.158)

0.035

Docetaxel cycles

0.926

(0.900–0.953)

0.026

0.943

(0.915–0.972)

0.011

 Prostatectomy

1

(reference)

 Radiation therapy

0.778

(0.580–1.141)

0.584

 Pre-chemotherapy

1

(reference)

 Post-chemotherapy

0.865

(0.524–1.430)

0.572

Radium-223 administration

0.803

(0.255–2.527)

0.707

Clinical trial participation

0.593

(0.417–0.843)

0.004

0.585

(0.429–0.797)

0.038